CD163L1 (CD163 molecule-like 1) is a scavenger receptor localized to the plasma membrane that serves as a marker of tissue-resident, anti-inflammatory macrophages 1. CD163L1+ macrophages exhibit an M2-oriented phenotype associated with IL-10 production and immunosuppressive properties, contrasting with pro-inflammatory CLEC5A+ macrophages 1. In healthy tissues (liver, colon, lean adipose tissue), CD163L1+ macrophages predominate and maintain tissue homeostasis 12. However, CD163L1 expression is dysregulated in inflammatory and malignant contexts: increased CD163L1+ macrophage infiltration occurs in inflammatory bowel disease, diverticulitis, and obesity-associated adipose tissue remodeling 132. In colorectal cancer liver metastasis, CD163L1+ macrophages interact with Th17 cells via the CCL4-CCR5 axis to promote tumor-supporting immune responses 4. CD163L1 expression is regulated by m6A methylation modifications; homocysteine-induced reduction in m6A methylation decreases CD163L1 levels, impairing M2 macrophage polarization and promoting atherosclerosis 5. Additionally, CD163L1 may serve as a potential therapeutic target in ovarian-related diseases 6. These findings position CD163L1 as both a critical mediator of macrophage immunomodulation and a clinically relevant biomarker in inflammatory and neoplastic diseases.